MedTrace Logo

A Real-world Study of Inetetamab for First-line Treatment of MBC

NCT05980208 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-08-08

No results posted yet for this study

Summary

This is a prospective, multicenter, real-world study aimed at evaluating the efficacy and safety of inetetamab+chemotherapy or inetetamab+pyrotinib+chemotherapy or inetetamab+pertuzumab+chemotherapy in the treatment of HER2 positive inoperable locally advanced or recurrent metastatic breast cancer. The research results will provide new targeted treatment strategies for HER2 positive breast cancer patients.

Conditions

Interventions

DRUG

Inetetamab

Inetetamab-based treatment for first-line treatment of HER2-positive MBC

Sponsors & Collaborators

  • Hunan Medical University General Hospital

    collaborator UNKNOWN

  • Hunan Cancer Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-12-31
Completion
2026-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05980208 on ClinicalTrials.gov